https://www.ndtvprofit.com/research-reports/pharma-q1-results-review-strong-overall-show-us-visibility-improves-nirmal-bang?utm_source=telegram&utm_medium=referral&utm_campaign=socialshare
Revlimid and price stabilisation drive U.S. growth; India business affected by seasonality and NLEM.